Eris Lifesciences Limited has successfully concluded its postal ballot voting process, with all four proposed resolutions receiving shareholder approval through remote e-voting that ended on December 24, 2025.

Postal Ballot Process Overview

The remote e-voting period commenced at 09:00 a.m. IST on November 25, 2025, and remained open until 17:00 hours IST on December 24, 2025. The company had initially issued the Postal Ballot Notice on November 24, 2025, which was subsequently updated through corrigenda dated December 5, 2025, and December 17, 2025.

Resolution Results Summary

All four resolutions were passed with overwhelming support from shareholders. The voting results demonstrate strong confidence from both promoter and public shareholders across different categories.

Resolution 1: Re-appointment of Whole-Time Director

The special resolution for re-appointing Mr. Krishnakumar Vaidyanathan as Whole-Time Director received substantial approval:

Resolution 2: Re-appointment of Independent Director

The special resolution to re-appoint Ms. Kalpana Unadkat as Independent Director also secured approval:

Resolution 3: Preferential Share Issuance

The special resolution for approval of issuance up to 23,06,372 fully paid-up equity shares on preferential basis for consideration other than cash received near-unanimous support:

Resolution 4: Related Party Transactions

The ordinary resolution to approve material related party transactions with Mr. Naishadh Shah was passed with strong support:

Compliance and Documentation

The voting results have been prepared in compliance with Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. All relevant documents, including the e-voting results and scrutinizer's report, have been uploaded on the company's website and the website of MUFG Intime India Private Limited, the registrar and transfer agent.

The successful completion of this postal ballot process enables Eris Lifesciences to proceed with its planned corporate actions, including the key appointments and the preferential share issuance, supporting the company's strategic initiatives.

Eris Lifesciences has informed the stock exchanges about the completion of Mr. Rajeev Dalal's tenure as Non-Executive Independent Director, which will conclude on December 18, 2025. The announcement was made through a regulatory filing under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Director Tenure Details

Mr. Rajeev Dalal (DIN: 00222650) was appointed as a Non-Executive Independent Director for a term of five consecutive years. His appointment was approved by the company's members at their Fifteenth Annual General Meeting held on September 1, 2021, with the tenure commencing from December 19, 2020.

Impact on Board Committees

Consequent upon the completion of Mr. Dalal's term as Non-Executive Independent Director, his membership and chairmanship in various committees of the Board will also cease to exist with effect from the close of business hours on December 18, 2025.

Company's Acknowledgment

The Board of Directors and Management of Eris Lifesciences have extended their sincere appreciation for the valuable contributions made by Mr. Rajeev Dalal during his five-year tenure as an Independent Director. The company has formally communicated this development to both BSE Limited and the National Stock Exchange of India Limited as part of its regulatory compliance obligations.

The filing was signed by Milind Talegaonkar, Company Secretary and Compliance Officer (Membership No: A26493), ensuring proper adherence to the disclosure requirements under the SEBI regulations.